ResearcherUniversitätsmedizin RostockNo recent work listed
Maria Schönrogge
Matched on OpenAlex author ID A5089575912. Sources: OpenAlex.
Their work
- Papers
- 5 (first author 2, last author 0)
- Trials
- 0
- Grants
- 0
- Labs led
- 0
- Collaborators
- 7
2016: 1 paper · 2017: none · 2018: 2 papers · 2019: none · 2020: 1 paper · 2021: none · 2022: 1 paper
Papers 5
- Targeting pancreatic cancer with combinatorial treatment of CPI-613 and inhibitors of lactate metabolism. Co-author DOI 10.1371/journal.pone.0266601↗
- Galloflavin Plus Metformin Treatment Impairs Pancreatic Cancer Cells. First author DOI 10.21873/anticanres.13936↗
- α-cyano-4-hydroxycinnamate impairs pancreatic cancer cells by stimulating the p38 signaling pathway. Co-author DOI 10.1016/j.cellsig.2018.03.015↗
- Blocking Autophagy in Cancer-Associated Fibroblasts Supports Chemotherapy of Pancreatic Cancer Cells. First author DOI 10.3389/fonc.2018.00590↗
- Analysis of Axin2 expression and function in murine models for pancreatic cancer. Co-author DOI 10.1186/s13578-016-0116-4↗
Closest collaborators
The 7 strongest of 7 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Dietmar Zechner · 5 shared papers, 2016–2022 · strength 0.55
- Paper Galloflavin Plus Metformin Treatment Impairs Pancreatic Cancer Cells. DOI 10.21873/anticanres.13936↗
- Paper Targeting pancreatic cancer with combinatorial treatment of CPI-613 and inhibitors of lactate metabolism. DOI 10.1371/journal.pone.0266601↗
- Paper α-cyano-4-hydroxycinnamate impairs pancreatic cancer cells by stimulating the p38 signaling pathway. DOI 10.1016/j.cellsig.2018.03.015↗
- Brigitte Vollmar · 5 shared papers, 2016–2022 · strength 0.55
- Paper Galloflavin Plus Metformin Treatment Impairs Pancreatic Cancer Cells. DOI 10.21873/anticanres.13936↗
- Paper Targeting pancreatic cancer with combinatorial treatment of CPI-613 and inhibitors of lactate metabolism. DOI 10.1371/journal.pone.0266601↗
- Paper α-cyano-4-hydroxycinnamate impairs pancreatic cancer cells by stimulating the p38 signaling pathway. DOI 10.1016/j.cellsig.2018.03.015↗
- Edgar Heinz Uwe Wendt · 3 shared papers, 2018–2022 · strength 0.38
- Paper Galloflavin Plus Metformin Treatment Impairs Pancreatic Cancer Cells. DOI 10.21873/anticanres.13936↗
- Paper Targeting pancreatic cancer with combinatorial treatment of CPI-613 and inhibitors of lactate metabolism. DOI 10.1371/journal.pone.0266601↗
- Paper Blocking Autophagy in Cancer-Associated Fibroblasts Supports Chemotherapy of Pancreatic Cancer Cells. DOI 10.3389/fonc.2018.00590↗
- Xianbin Zhang · 3 shared papers, 2018–2022 · strength 0.31
- Paper Targeting pancreatic cancer with combinatorial treatment of CPI-613 and inhibitors of lactate metabolism. DOI 10.1371/journal.pone.0266601↗
- Paper α-cyano-4-hydroxycinnamate impairs pancreatic cancer cells by stimulating the p38 signaling pathway. DOI 10.1016/j.cellsig.2018.03.015↗
- Paper Blocking Autophagy in Cancer-Associated Fibroblasts Supports Chemotherapy of Pancreatic Cancer Cells. DOI 10.3389/fonc.2018.00590↗
- Simone Kumstel · 3 shared papers, 2018–2022 · strength 0.31
- Paper Targeting pancreatic cancer with combinatorial treatment of CPI-613 and inhibitors of lactate metabolism. DOI 10.1371/journal.pone.0266601↗
- Paper α-cyano-4-hydroxycinnamate impairs pancreatic cancer cells by stimulating the p38 signaling pathway. DOI 10.1016/j.cellsig.2018.03.015↗
- Paper Blocking Autophagy in Cancer-Associated Fibroblasts Supports Chemotherapy of Pancreatic Cancer Cells. DOI 10.3389/fonc.2018.00590↗
- Tim Schreiber · 1 shared paper, 2022 · strength 0.14
- Robert Jaster · 1 shared paper, 2018 · strength 0.08
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.